Current FDA approved anti-epileptic drugs that target these pathways fail to control seizures in 30% of patients,
This Summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key and/or essential features of the claimed subject matter. Also, this Summary is not intended to limit the scope of the claimed subject matter in any manner. Aspects of the disclosure pertain to methods and compositions for treating seizures.
Epilepsy is a neurological disorder defined by recurrent spontaneous seizures. Approximately 1% of people in the US have epilepsy. Seizures are associated with cell toxicity, hyperexcitability and death. Anti-epileptic drugs act primarily on ion channels and receptors for calcium, sodium, potassium, glutamate and GABA. Current FDA approved anti-epileptic drugs that target these pathways fail to control seizures in 30% of patients.
In one embodiment, a method treats seizure by restoring mitochondrial function in seizure-genic brain regions. As used herein, the term "seizure-genic brain region" may be any region of the brain where mitochondrial function may be impaired, leading to a seizure. For instance, seizures may originate from an epileptic focus where mitochondrial function is impaired, a small portion of the brain that serves as the irritant driving the epileptic response. Seizures may also originate from many independent foci (multifocal epilepsies) where mitochondrial function may be impaired.